Geneva, June 4 -- International Clinical Trials Registry received information related to the study (NCT06984718) titled 'A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC' on May 15.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Akeso
Condition:
HCC
Hepatocellular Carcinoma
Intervention:
Biological: AK104+lenvatinib
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: June 25, 2025
Target Sample Size: 120
To know more, visit https://clinicaltrials.gov/ct2/show/NCT06984718
Published by HT Digital Content Services with permissio...